KNOCKOUT MICE FOR DIFFERENT GENES AND THEIR USE FOR GENE CHARACTERIZATIO

• Main Authors: PAYNE, BOBBY, JOE, SPARKS, MARY JEAN, FILVAROFF, ELLEN, JUNUTULA, JAGATH, REDDY, DESAUVAGE, FREDERIC, SHI, ZHENG-ZHENG, VOGEL, PETER
• Format: Patent
• Language: English; French
• Published: 09.10.2008
• Subjects: AGRICULTURE; ANIMAL HUSBANDRY; BEER; BIOCHEMISTRY; CARE OF BIRDS, FISHES, INSECTS; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FISHING; FORESTRY; HUMAN NECESSITIES; HUNTING; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NEW BREEDS OF ANIMALS; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; SPIRITS; TESTING; TRAPPING; VINEGAR; WINE

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO844, PRO1131 or PRO5992 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. La présente invention concerne des animaux transgéniques ainsi que des compositions et des procédés se rapportant à la caractérisation de la fonction génique. De manière spécifique, cette invention porte sur des souris transgéniques comportant des disruptions dans les gènes PRO844, PRO1131 ou PRO5992. Ces études in vivo et ces caractérisations peuvent permettre d'identifier et de découvrir avec intérêt des substances thérapeutiques et/ou des traitements utiles dans la prévention, l'amélioration ou la correction de maladies ou de dysfonctionnements associés aux disruptions géniques tels que les troubles neurologiques; les troubles cardio-vasculaires, endothéliaux ou angiogéniques; les anomalies de l'oeil; les troubles immunologiques; les pathologies oncologiques; les anomalies ou les dérèglements du métabolisme osseux; les dérèglements du métabolisme des lipides; ou les troubles de la croissance.